- Presenter: Prof Nancy Haigwood
- Topic: Antibodies and Change Agents in HIV: Good News for Vaccines
- Date: Tuesday 21 February 2017
- Seminar Time: 12:30 - 1:30pm
- Light lunch: 11:45am in the seminar room foyer, level 2, TRF Building
- Venue: Seminar Room 1, Level 2, TRF Building, Monash Medical Centre
- Flyer
- To book a time to meet with Prof Haigwood: email andrea.johannessen@monash.edu
- Further information: visit the CID Weekly Seminar Series website
Speaker profile:
Prof Nancy Haigwood, Director, Oregon National Primate Research Center (ONPRC), Oregon Health & Science University (OHSU), Professor, Pathobiology & Immunology Division, ONPRC, OHSU, Adjunct Professor, Molecular Microbiology & Immunology, School of Medicine, OHSU
For the last 30 years Prof Haigwood has been actively engaged in vaccine discovery and immunotherapy research for in nonhuman primate (NHP) models for HIV/AIDS. Prof Haigwood co-developed one of the first HIV vaccines, gp120 produced in CHO cells, while at Chiron Corporation (now Novartis) and has maintained a continuously funded laboratory that is focused on antibody-based therapies and Envelope-based vaccines to elicit protective antibodies. Since leaving industry in 1997, Prof Haigwood has led numerous and continuing individual and collaborative program grants as Principal Investigator, including serving as PI of a P01 “HIVRAD” vaccine grant to discover novel HIV Envelope immunogens. Expertise in the laboratory extends to DNA-based and viral vaccines, as well as recombinant monomeric and trimeric antigen design and production in 293 cells (and purification) for use in vaccine studies. Prof Haigwood's laboratory has recently shown that potent human neutralizing monoclonal antibodies can change the course of SHIV infection in infant macaques, directly killing newly established infected cells in vivo and preventing the establishment of a permanent viral reservoir.
No comments:
Post a Comment